Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Hazy vision; This is a spontaneous report from a contactable consumer, received from the regulatory authority. The regulatory authority report number is GB-MHRA-WEBCOVID-202106031201534720-MAWT8, Safety Report Unique Identifier GB-MHRA-ADR 25420957. A 47-year-old male patient received the first dose of BNT162B2 (Pfizer-BIONTECH COVID-19 Vaccine), via an unspecified route of administration on 03Jun2021 (at the age of 47-years-old) (Batch/Lot Number: EW,109) as a single dose for COVID-19 immunization. Medical history included suspected COVID-19 from 29Dec2019 to 14Jan2020 and eczema. The patient has not had a COVID-19 test and was not enrolled in a clinical trial. Concomitant medications included betamethasone dipropionate, salicylic acid (DIPROSALIC) taken for eczema and an unspecified medication (described as being applied to the patient''s scalp and was applied the day before having the vaccine). The patient experienced hazy vision on 03Jun2021 which started approximately 20 minutes after receiving the injection. The patient has not tested positive for COVID-19 since having the vaccine. Outcome of the event was not recovered. The case was reported as serious (medically significant). No follow-up attempts are possible. No further information is expected.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166